Approval Date: Jul 2022
Indicated for topical treatment of plaque psoriasis
Approval Date: Jul 2022
Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.
Approval Date: Jun 2022
Indicated for the treatment of partial-onset seizures.
Approval Date: Jun 2022
A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.
Approval Date: Jun 2022
Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.
Approval Date: May 2022
A steroid-free topical indicated for treatment of plaque psoriasis
Approval Date: May 2022
Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing
Approval Date: May 2022
Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise
Approval Date: Apr 2022
Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder
Approval Date: Mar 2022
A first-time generic for Vimpat, this drug treats partial onset seizures
